胞二磷胆碱联合血栓通治疗老年慢性脑供血不足50例疗效观察

目的 观察胞二磷胆碱联合血栓通对老年慢性脑供血不足的临床疗效.方法 将我院2009-01～2011-01收治的椎基底动脉供血不足患者100例随机分为对照组50例,给予胞二磷胆碱0.5g加入0.9％氯化钠250mL中静滴,1次/d;治疗组50例,在对照组治疗的基础上加用血栓通注射液10 mL加入0.9％氯化钠注射液250...     

盐酸丁咯地尔联合血栓通治疗椎基底动脉供血不足疗效观察

目的 观察盐酸丁咯地尔联合血栓通治疗椎基底动脉供血不足(VBI)的临床疗效.方法 随机将87例病人分为治疗组(45例)和对照组(42例),治疗组应用盐取丁咯地尔注射液100 mg加入生理盐水250 mL中静滴,1次/d,血栓通冻干粉针450 mg加入5%葡萄糖250 mL中静滴,1次/d;对照组应用复方丹参注射液250 mL静滴,1次/d;2组均连用10 d,其余常规治疗相同.结果 治疗组痊愈26例,有效18例,总有效率98%;对照组痊愈15例,有效24例,总有效率93%,治疗组疗效优于对照组(P＜0.05).结论 盐酸丁咯地尔联合血栓通治疗椎基底动脉供血不足有良好的临床疗效,可以临床广泛应用.     

法舒地尔治疗椎基底动脉供血不足性眩晕

目的 对法舒地尔治疗椎基底动脉供血不足性眩晕的疗效进行临床观察. 方法 采用随机对照方法,治疗组予法舒地尔30mg,加入5%葡萄糖液250ml中静滴,1次/d;对照组予尼莫地平,加入5%葡萄糖液250ml中静滴,1次/d.疗程为14d.2组针对部分特殊病例高血糖、高血压等情况对症治疗.结果 经治疗,治疗组显效率84.0%,好转率12.0%,总有效率达96.0%,显效率优于对照组(P＜0.05),总有效率差异无显著性(P＞0.05).治疗中未出现任何不良反应.结论 法舒地尔治疗椎基底动脉供血不足性眩晕效果确切,安全可靠,值得推广.     

盐酸法舒地尔注射液治疗椎基底动脉供血不足疗效观察

目的观察盐酸法舒地尔注射液治疗椎基底动脉供血不足的临床疗效和安全性。方法选取我院收治符合入选标准的106例椎基底动脉供血不足患者,分成实验组和对照组。实验组每日给予羟乙基淀粉250mL静滴,1次/d,法舒地尔注射液30mg静滴,2次/d;对照组每日给予羟乙基淀粉250mL静滴,1次/d,丁咯地尔注射液0.2g静滴,1次/d。辅以对症支持治疗,疗程均为14d,观察临床疗效及不良反应。结果与治疗前比较,实验组椎动脉和基底动脉血流速度均有明显加快,治疗前后差异具有统计学意义(P<0.05);与对照组比较,实验组治疗有效率无统计学意义(P>0.05)。结论单一应用盐酸法舒地尔注射液治疗椎基底动脉供血不足效果显著,无严重不良反应发生。     

法舒地尔治疗椎基底动脉供血不足疗效观察

目的观察盐酸法舒地尔对椎基底动脉供血不足(VBI)的疗效。方法选择VBI患者70例,随即分为2组,每组35人,治疗组应用盐酸法舒地尔注射液30 mg加入生理盐水或5%葡萄糖250 mL中静滴,1次/d;对照组应用复方丹参20mL加入盐酸倍他司汀500 mL中静滴,1次/d,10 d为一疗程,治疗前后观察临床疗效。结果治疗组总有效率94.3%,对照组总有效率74.4%。结论酸法舒地尔治疗VBI是安全、有效的。     

舒血宁联合复方右旋糖苷40治疗后循环缺血疗效观察

目的观察舒血宁联合复方右旋糖酐40治疗后循环缺血的疗效。方法将182例后循环缺血性眩晕患者随机分为2组。治疗组给予舒血宁注射液20mL加入250mL生理盐水和复方右旋糖酐40注射液250mL静滴,1次/d,连用14d。对照组给予红花注射液30 mL加入生理盐水250 mL中静滴,1次/d,连用14d。结果治疗组总有效率91.2%,对照组为74.7%,2组比较差异有统计学意义(P0.05)。2组治疗后与治疗前相比两侧椎基底动脉平均血流速度(Vm)、基底动脉阻力指数(RI)均改善(P0.05)。结论舒血宁联合复方右旋糖苷40治疗后循环缺血可明显改善患者症状、脑部血流,值得临床应用。     

丁咯地尔联合脉络宁治疗椎基底动脉供血不足性眩晕58例疗效观察

目的 观察丁咯地尔联用脉络宁治疗椎基底动脉供血不足的疗效.方法 收58例椎基底动脉供血不足随机分成2组各29例,对照组仅用脉络宁20ml+5%葡萄糖或0.9%氯化钠250ml静滴,1次/d,共10d;治疗组在脉络宁的基础上加用丁咯地尔0.2g+培他啶氯化钠500ml静滴,1次/d,共10d.结果 冶疗组和对照组疗程结束后总有效率比较差异有统计学意义(P＜0.01).结论 丁咯地尔联合脉络宁治疗椎基底动脉供血不足疗效确切值得临床应用.     

长春西汀治疗椎基底动脉供血不足性眩晕38 例疗效观察

目的 探讨长春西汀注射液治疗椎基底动脉供血不足性眩晕的疗效.方法 将76例椎基底动脉供血不足性眩晕的患者分为2组,治疗组用长春西汀注射液40 mg/d 生理盐水250ml静滴 ,而对照组用复方丹参注射液20ml/d 生理盐水250ml静滴,共用14d.结果 治疗组与对照组有效率差异有统计学意义(P＜0.01);治疗后椎基底动脉血流动力学明显改善(P＜0.05).结论 长春西汀注射液治疗椎基底动脉供血不足性眩晕疗效显著,且不良反应少、复发率低,值得推广使用.     

丁咯地尔联合奥扎格雷钠治疗椎基底动脉供血不足性眩晕的疗效观察

目的 观察丁咯地尔联合奥扎格雷钠治疗椎基底动脉供血不足性眩晕的疗效.方法 60例符合条件的病例随机分为治疗组和对照组,各30例.治疗组给予丁咯地尔200 mg加入生理盐水500 ml中静滴,1次/d;奥扎格雷钠80 mg加入生理盐水100 ml中静滴,2次/d,14 d为一疗程.对照组给予盐酸倍他司汀注射液500 ml(含倍他司汀0.02 g,氯化钠4.5 g)静滴,1次/d;肠溶阿司匹林75 mg口服,1次/d,14 d为一疗程.一疗程结束后评定疗效.结果 治疗组疗效高于对照组(P＜0.05).结论 丁咯地尔联合奥扎格雷钠治疗椎基底动脉供血不足性眩晕的疗效可靠,可在临床上推广应用.     

前列地尔联合天麻素治疗后循环缺血疗效观察

目的观察前列地尔联合天麻素治疗椎基动脉供血不足的疗效。方法 126例后循环缺血的患者随机分为前列地尔联合天麻素治疗组和单一药物对照组。治疗组给予前列地尔10μg加入到5%葡萄糖液250mL静滴,天麻素0.6g加入到0.9%氯化钠注射液250mL静滴,1次/d;对照一组单用前列地尔,对照二组单用天麻素,14d为1个疗程。7d、14d后评定疗效。结果治疗组总有效率90.9%,对照一组71.4%,对照二组70.0%。治疗组疗效高于对照组,差异有统计学意义(P<0.05)。结论前列地尔联合天麻素治疗后循环缺血疗效可靠,可临床推广应用。     

谷红注射液治疗急性脑梗死60例疗效观察

目的观察谷红注射液治疗急性脑梗死的临床疗效。方法选择我院2005年120例急性脑梗死患者，随机分成治疗组和对照组。治疗组60例给予谷红注射液20ml加入0．9％氯化钠溶液250ml静滴，1次／d；对照组给予复方丹参注射液20ml加入0．9％氯化钠溶液250ml静滴，1次／d。2组患者均给予脱水剂、脑细胞活化剂等基础治疗，2组疗程均为15d。结果治疗组和对照组神经功能缺损评分差异有统计学意义（P〈0．01），2组血液流变学指标比较有统计学意义（P〈0．01）。结论谷红注射液治疗急性脑梗死安全有效。     

Efficacy of cattle encephalon glycoside and ignotin in patients with acute cerebral infarction: a randomized,double-blind,parallel-group,placebo-controlled study

Cattle encephalon glycoside and ignotin(CEGI)injection is a compound preparation formed by a combination of muscle extract from hea lthy rabbits and brain gangliosides from cattle,and it is generally used as a neuroprotectant in the treatment of central and peripheral nerve injuries.However,there is still a need for high-level clinical evidence from large samples to support the use of CEGI.We therefore carried out a prospective,multicenter,randomized,double-blind,parallel-group,placebo-controlled study in which we recruited 319 patients with acute cerebral infarction from 16 centers in China from October 2013 to May 2016.The patients were randomized at a 3:1 ratio into CEGI(n=239;155 male,84 female;61.2±9.2 years old)and placebo(n=80;46 male,34 female;63.2±8.28 years old)groups.All patients were given standard care once daily for 14 days,including a 200 mg aspirin enteric-coated tablet and 20 mg atorvastatin calcium,both taken orally,and intravenous infusion of 250–500 mL 0.9%sodium chloride containing 40 mg sodium tanshinone IIA sulfonate.Based on conventional treatment,patients in the CEGI and placebo groups were given 12 mL CEGI or 12 mL sterile water,respectively,in an intravenous drip of 250 mL 0.9%sodium chloride(2 mL/min)once daily for 14 days.According to baseline National Institutes of Health Stroke Scale scores,patients in the two groups were divided into mild and moderate subgroups.Based on the modified Rankin Scale results,the rate of patients with good outcomes in the CEGI group was higher than that in the placebo group,and the rate of disability in the CEGI group was lower than that in the placebo group on day 90 after treatment.In the CEGI group,neurological deficits were decreased on days 14 and 90 after treatment,as measured by the National Institutes of Health Stroke Scale and the Barthel Index.Subgroup analysis revealed that CEGI led to more significant improvements in moderate stroke patients.No drug-related adverse events occurred in the CEGI or placebo groups.In conclusion,CEGI may be a safe and effective treatment for acute cerebral infarction patients,especially for moderate stroke patients.This study was approved by the Ethical Committee of Peking University Third Hospital,China(approval No.2013-068-2)on May 20,2013,and registered in the Chinese Clinical Trial Registry(registration No.ChiCTR1800017937).     

大剂量利多卡因治疗椎-基底动脉供血不足性眩晕86例疗效分析

目的 :观察利多卡因治疗椎 基底动脉供血不足性眩晕的疗效。方法 :选择椎 基底动脉供血不足性眩晕患者 15 6例。治疗组 86例 ,应用利多卡因 0 2 -0 4g加入 5 %葡萄糖内静滴 14天 ,一日 1次。对照组 70例 ,应用维生素、苯海拉明 ,并用低分子右旋糖酐 复方丹参注射液静滴 ,一日 1次 ,14天一疗程。结果 :治疗组疗效明显高于对照组 (P <0 .0 5 )。结论 :大剂量利多卡因治疗椎 基底动脉供血不足性眩晕疗效佳。     

重心动摇平衡仪治疗急性椎-基底动脉供血不足性眩晕的临床观察

目的探讨人体重心动摇平衡仪在椎-基底动脉供血不足性眩晕患者治疗中的应用价值.方法将2004年8月～2005年1月西京医院神经内科病房住院的椎-基底动脉供血不足性眩晕患者80例随机分为治疗组和对照组,2组药物治疗相同,治疗组同时接受日本Anima公司生产的EAB-100型重心动摇平衡仪康复治疗,每周训练3次,每次为15～30 min,共2周.结果治疗至第1,2周时2组重心动摇面积均在减小,治疗组重心动摇面积显著小于对照组(P＜0.05),1、2周时治疗组症状改善有效率分别为88.3%、96.5%,显著高于对照组67.6%、75.7%(P＜0.05).结论给椎-基底动脉供血不足性眩晕患者服用药物治疗的同时,给予重心动摇平衡仪康复训练,能促进患者平衡功能障碍的恢复和显著改善患者急性期的眩晕症状.     

赛莱乐对多梗死性痴呆患者CD62P、CD63P、P10、DI的变化影响

目的观察赛莱乐治疗对多梗死性痴呆(MID)患者CD62P、CD63、P10、DI变化的影响.方法将禁用阿司匹林及尼莫地平的78例MID患者分2组,治疗组48例,应用赛莱乐150mg静滴,1次/日×15天;对照组30例,复方丹参20ml静滴,1次/日×15天,观测治疗前、后CD62P、CD63、P10及DI变化.结果治疗后治疗组CD62P、CD63、P10表达明显降低,DI明显增强(P＜0.01)与对照组比差异显著(P＜0.05).CD62、P10与DI呈负相关(P＜0.05),CD63与DI无相关.结论赛莱乐可降低CD62P、CD63、P10表达,抑制血小板活化,增强红细胞变形能力,对MID恢复有益.     

前列地尔治疗脑心综合征的疗效观察

目的观察前列地尔治疗脑心综合征患者的疗效。方法选择河南省胸科医院2015-09—2016-09住院符合脑心综合征诊断标准的168例患者,随机分为观察组(84例)和对照组(84例)。2组均采用内科常规治疗,观察组采取前列地尔10μg加入0.9%氯化钠注射液100mL内静滴,bid,3周一疗程。观察2组临床疗效。结果 2组治疗后NIHSS评分显著下降,观察组较对照组明显下降(P0.05)。BI评分显著升高,观察组较对照组明显升高(P0.05)。2组心脏功能的疗效比较观察组明显高于对照组(P0.05)。结论前列地尔可以提高脑心综合征患者的疗效。     

黛力新治疗椎-基底动脉供血不足性眩晕的观察

目的 探讨黛力新治疗椎-基底动脉供血不足(VBI) 性眩晕的临床疗效.方法 对照组急性期(1～2周)予葛根素40ml加入生理盐水250ml静滴,1次/d,共使用1～2周,并口服西比灵5 mg,qn,谷维素20 mg,tid,缓解期停用葛根素,继续按方法口服西比灵和谷维素治疗,治疗组在对照组的基础上加用黛力新口服,急性期早上及中午各服1片,缓解期改为早上口服1片/d.观察2组疗效和症状反复情况.结果 治疗组总有效率(治愈 有效)为94.1 %,对照组为66.6 % ,经统计学处理,2组差异有统计学意义(P＜ 0.01);12周内2组患者眩晕症状复发率黛力新组低于对照组(P ＜ 0.01) .结论 黛力新治疗椎-基底动脉供血不足性眩晕起效快、疗效好,症状反复率低.     

A Clinical study on the treatment of Cerebral Infarct with Naloxone

OBJECTIVE: Naloxone and complex Danshen were used to treat cerebral infart in order to compare two groups′ Clinical effectiveness. BACKGROUND:The treatment of cervral infart with Naloxone is reported more often in abroad than in domestic. METHODS:144 cases were divided into two group randomly group treated with Naloxone: 74 cases (male 39 cases,female 33 cases,) average age 64.5yr. control group:70 cases (male 37 cases, female 33 cases), average age 65yr. 0.8mgNaloxone which was soluted in 250ml 0.9% Natrii chloride was used in the trcatment group by intravenous infusion, Qd, and the treatment lasted 14 days, On before and 4W and 8W both aftcr treatment, clotting time and blood flow dynamics were investigated. According to NDS and DLA standards, clinical effectiveness was compared and was studied by t test statistic method. RESULTS:Thc total response rate is 93.2% in Naloxonegroup, and 77.1% in control group (P＜0. 05), The differencebetween two groups is statistically significant. CONCLUSION: The treatment of cercral infart with Naloxone is more effiecfive than with complex Danshen     

法舒地尔通过诱导EAE小鼠Occludin表达抑制其炎性细胞浸润

目的观察法舒地尔(Fasudil)对实验性自身免疫性脑脊髓炎(EAE)小鼠模型的治疗效果并探讨其作用机制。方法采用髓鞘少突胶质细胞糖蛋白35-55(MOG35-55)免疫建立国际标准的小鼠EAE模型。将免疫后的42只雌性C57BL/6小鼠随机分为EAE组、Fasudil早期治疗组和Fasudil晚期治疗组。Fasudil早期治疗组即免疫后第3天按体质量40mg/(kg.d)腹腔注射Fasudil,1次/d,至免疫后30d;Fasudil晚期治疗组即免疫后首只小鼠出现症状即开始腹腔注射Fasudil,注射方法和剂量同Fasudil早期治疗组;与晚期治疗组给药同一时间,给予EAE组等量生理盐水作为对照。免疫后隔天观察各组小鼠临床评分和体质量变化。于免疫30d后处死动物,分离小鼠脊髓腰膨大和脑冠状位中部1/3处做冷冻切片,行HE染色和免疫荧光染色。同时提取小鼠脊髓蛋白检测Occludin蛋白的表达。结果 Fasudil可改善EAE的临床症状,抑制脑血管内皮细胞Rho激酶(ROCK)活性。与EAE组相比,Fasudil早期治疗组和晚期治疗组CD31阳性内皮细胞上p-MYPT1表达均减弱(P<0.01,P<0.05),起病时间均延长(P<0.01,P<0.05),脊髓Occludin蛋白表达均增加(P<0.05)。结论 Fasudil对EAE具有治疗的潜能,其机制可能为通过抑制血管内皮细胞ROCK活性,参与诱导内皮细胞紧密连接蛋白Occludin的表达,从而抑制炎性细胞的中枢浸润,最终阻止疾病的发生和发展。     

Vertigo of vascular origin. Clinical and electronystagmographic features in 84 cases

We reviewed the clinical and electronystagmographic findings of 84 patients who presented to our neuro-otology clinic with vertigo of presumed cerebrovascular origin. There was a surprisingly high incidence of isolated episodes of vertigo (abrupt in onset, lasting minutes). In some patients these episodes preceded other symptoms of vertebrobasilar insufficiency or infarction by months. Peripheral vestibular abnormalities were common on electronystagmographic testing; 42% had unilateral hypoexcitability to caloric stimulation. We conclude that the vestibular labyrinth is selectively vulnerable to ischemia within the vertebrobasilar system.